---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-029438"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2023-06-22T23:59:59+00:00"
generated_at: "2026-06-13T19:34:17.987491+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sarepta sets wholesale acquisition cost for ELEVIDYS at $3.2 million

## Summary
- Wholesale acquisition cost (gross price) of gene therapy ELEVIDYS set at $3.2 million.
- Indicated for ambulatory pediatric patients aged 4-5 years with DMD gene mutation.
- Price disclosed during investor webcast on June 22, 2023.
- NASDAQ ticker: SRPT.

## SEC filing metadata
- accession: 0000950170-23-029438
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2023-06-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000095017023029438/0000950170-23-029438-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000095017023029438/srpt-20230622.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-029438
- JSON: https://secwatch.observer/filing/0000950170-23-029438.json
- Plain text: https://secwatch.observer/filing/0000950170-23-029438.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.